Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P5TG
|
|||
| Former ID |
DIB011819
|
|||
| Drug Name |
Multi-epitope peptide melanoma vaccine
|
|||
| Synonyms |
Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1] | |
| Company |
University of Pittsburgh
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MART-1 melanoma antigen (MLANA) | Target Info | . | [2] |
| Melanocytes lineage-specific antigen GP100 (PMEL) | Target Info | . | [2] | |
| Tyrosinase (TYR) | Target Info | . | [2] | |
| BioCyc | (S)-reticuline biosynthesis | |||
| Eumelanin biosynthesis | ||||
| L-dopachrome biosynthesis | ||||
| KEGG Pathway | Tyrosine metabolism | |||
| Riboflavin metabolism | ||||
| Metabolic pathways | ||||
| Melanogenesis | ||||
| Pathwhiz Pathway | Riboflavin Metabolism | |||
| Tyrosine Metabolism | ||||
| WikiPathways | Dopamine metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health. | |||
| REF 2 | Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.